Novel and Evolving Therapies in the Treatment of Malignant Phaeochromocytoma: Experience with the mTOR Inhibitor Everolimus (RAD001)

Abstract

Phaeochromocytoma and paraganglioma are rare neuroendocrine tumours (NETS). They may be benign or malignant but the pathological distinction is mainly made when metastases are present. Available treatments in the form of surgery, chemotherapy, and radionuclide therapy may improve symptoms and biochemical markers, but the results for the control of tumour bulk are less favourable. Furthermore, responses to treatment are frequently short-lived. This short review outlines the main molecular and histological features of malignant phaeochromocytoma and the difficulties in differentiating between benign and malignant disease. We list current therapies used for malignant pheochromocytoma; however, these generally achieve relatively low success rates. Hence, there is a need for new and more effective therapies. In vitro studies have implicated the PI3/Akt/mTOR pathway in the pathogenesis of malignant NETS, including phaeochromocytoma. Everolimus (RAD001, Novartis UK) is a compound that inhibits mTOR (mammalian Target Of Rapamycin) signalling. We have used RAD001 in four patients with progressive malignant paraganglioma/phaeochromocytoma in addition to other therapies (with institutional approval for compassionate use), and evaluated the effects of this treatment. We outline these four cases and review the theoretical background for this therapy, although the outcomes were relatively disappointing.

Key words

phaeochromocytoma - temozolomide - radiopharmaceuticals - sunitinib - everolimus

References

• 1 Harthill JE, Pozuelo RM, Milne FC, MacKintosh C. Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells.  Biochem J. 2002;  368 565-572
• 2 WHO classification of tumours – Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press 2004
• 3 Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young  Jr WF. Malignant pheochromocytoma: current status and initiatives for future progress.  Endocr Relat Cancer. 2004;  11 423-436
• 4 Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation.  Hypertension. 1997;  29 1133-1139
• 5 Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A, Niccoli-Sire P, Richard S, Rohmer V, Sadoul JL, Strompf L, Schlumberger M, Bertagna X, Plouin PF, Jeunemaitre X, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma or functional paraganglioma.  J Clin Oncol. 2005;  23 8812-8818
• 6 Srirangalingam U, Khoo B, Walker L, Macdonald F, Skelly R, George E, Spooner D, Johnston L, Monson J, Grossman A, Drake W, Akker S, Pollard P, Plowman N, Avril N, Berney D, Burrin J, Reznek R, Kumar VK, Maher E, Chew S. Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours.  Endocr Relat Cancer. 2009;  , [Epub ahead of print]
• 7 Mornex R, Badet C, Peyrin L. Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990.  J Endocrinol Invest. 1992;  15 643-649
• 8 Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, Sidhu SB. Pheochromocytoma: current approaches and future directions.  Oncologist. 2008;  13 779-793
• 9 Goldstein RE, O’Neill JA Jr, Holcomb III GW, Morgan III WM, Neblett III WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott  Jr HW. Clinical experience over 48 years with pheochromocytoma.  Ann Surg. 1999;  229 755-764
• 10 Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.  Endocr Relat Cancer. 2007;  14 569-585
• 11 Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up.  Surg Oncol Clin N Am. 1998;  7 765-789
• 12 Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.  J Endocrinol Invest. 1997;  20 648-658
• 13 Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.  Endocr Relat Cancer. 2005;  12 683-699
• 14 Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.  Ann Intern Med. 1988;  109 267-273
• 15 Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].  Clin Endocrinol (Oxf). 2001;  55 47-60
• 16 Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands.  Clin Oncol (R Coll Radiol). 2001;  13 361-366
• 17 Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.  J Clin Oncol. 2006;  24 401-406
• 18 Gross DJ, Munter G, Bitan M, Siegal T, Gabizon A, Weitzen R, Merimsky O, Ackerstein A, Salmon A, Sella A, Slavin S. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.  Endocr Relat Cancer. 2006;  13 535-540
• 19 Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.  J Clin Endocrinol Metab. 2009;  94 386-391
• 20 Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitnib in the treatment of malignant paraganglioma/pheochromocytoma (MPP).  J Clin Endocrinol Metab. 2009;  94 5-9
• 21 Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives.  Ann Oncol. 2005;  16 525-537
• 22 Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1.  Science. 2008;  320 1496-1501
• 23 Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed.  Clin Pharmacol Ther. 2007;  82 381-388
• 24 Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira Jr A, Dalino P, Salahuddin N, Korbonits M, Grossman AB. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6 K pathway in a neuro-endocrine tumour cell Line.  Neuroendocrinology. 2008;  87 168-181
• 25 Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L, Parsons R. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.  Proc Natl Acad Sci USA. 2001;  98 10320-10325
• 26 Fassnacht M, Weismann D, Ebert S, Adam P, Zink M, Beuschlein F, Hahner S, Allolio B. AKT is highly phosphorylated in pheochromocytomas but not in benign adrenocortical tumors.  J Clin Endocrinol Metab. 2005;  90 4366-4370
• 27 Thompson JE, Thompson CB. Putting the rap on Akt.  J Clin Oncol. 2004;  22 4217-4226
• 28 Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.  Int J Cancer. 2003;  104 233-237
• 29 Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.  J Clin Oncol. 2008;  26 4311-4318
• 30 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.  Lancet. 2008;  372 449-456
• 31 Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.  Eur J Cancer. 2008;  44 84-91

Correspondence